Company news

Sona Nanotech, Inc. news in 2025

Sona Nanotech, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

October 20, 2025

Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

October 17, 2025

Sona Provides Update on First-In-Human Clinical Trial

August 25, 2025

Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval

July 23, 2025

First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy

July 7, 2025

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

June 27, 2025

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

June 16, 2025

Sona Successfully Completes FDA-Required Toxicity Study

May 27, 2025

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

May 15, 2025

BioVaxys and Sona Nanotech Enter Research Collaboration

May 7, 2025

Sona Nanotech Announces Annual Options Grants

May 1, 2025

Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model

March 19, 2025

Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11

March 6, 2025

Decks in 2025